Chevy Chase Trust Holdings LLC Buys 9,043 Shares of Johnson & Johnson $JNJ

Chevy Chase Trust Holdings LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,401,388 shares of the company’s stock after buying an additional 9,043 shares during the quarter. Johnson & Johnson makes up 0.6% of Chevy Chase Trust Holdings LLC’s holdings, making the stock its 20th biggest holding. Chevy Chase Trust Holdings LLC owned approximately 0.06% of Johnson & Johnson worth $214,062,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the company. Ellis Investment Partners LLC raised its holdings in Johnson & Johnson by 0.7% in the 2nd quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock valued at $1,307,000 after buying an additional 62 shares during the last quarter. Cypress Wealth Services LLC raised its stake in shares of Johnson & Johnson by 0.9% during the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock valued at $1,013,000 after acquiring an additional 62 shares during the last quarter. Horizon Bancorp Inc. IN lifted its holdings in shares of Johnson & Johnson by 11.2% during the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company’s stock worth $97,000 after purchasing an additional 64 shares during the period. Global Strategic Investment Solutions LLC grew its stake in shares of Johnson & Johnson by 3.5% in the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company’s stock worth $294,000 after purchasing an additional 65 shares during the last quarter. Finally, JSF Financial LLC increased its holdings in Johnson & Johnson by 2.2% in the second quarter. JSF Financial LLC now owns 2,993 shares of the company’s stock valued at $457,000 after purchasing an additional 65 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $193.27 on Friday. The firm has a 50 day moving average of $180.49 and a 200-day moving average of $164.86. The company has a market cap of $465.45 billion, a price-to-earnings ratio of 18.65, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.40.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. On average, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on JNJ. The Goldman Sachs Group upped their price target on Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday, October 9th. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Morgan Stanley set a $190.00 price target on shares of Johnson & Johnson in a report on Wednesday. Argus set a $210.00 price objective on shares of Johnson & Johnson in a research note on Wednesday. Finally, Citigroup increased their price objective on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $199.59.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.